BARD1 and breast carcinoma: To further confirm the clinical relevance of the above findings, we analyzed the expression of BARD1 and BRCA1 in 27 paired primary and relapsed tumor samples from recurrent breast cancer patients who underwent adjuvant tamoxifen treatment and had their recurrent tumors biopsied or resected.